Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,419 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
Maddocks KJ, Ruppert AS, Lozanski G, Heerema NA, Zhao W, Abruzzo L, Lozanski A, Davis M, Gordon A, Smith LL, Mantel R, Jones JA, Flynn JM, Jaglowski SM, Andritsos LA, Awan F, Blum KA, Grever MR, Johnson AJ, Byrd JC, Woyach JA. Maddocks KJ, et al. Among authors: gordon a. JAMA Oncol. 2015 Apr;1(1):80-7. doi: 10.1001/jamaoncol.2014.218. JAMA Oncol. 2015. PMID: 26182309 Free PMC article.
Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study.
Lozanski G, Ruppert AS, Heerema NA, Lozanski A, Lucas DM, Gordon A, Gribben JG, Morrison VA, Rai KM, Marcucci G, Larson RA, Byrd JC. Lozanski G, et al. Among authors: gordon a. Leuk Lymphoma. 2012 Sep;53(9):1743-8. doi: 10.3109/10428194.2012.668683. Epub 2012 Jun 2. Leuk Lymphoma. 2012. PMID: 22369572 Free PMC article.
BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia.
Woyach JA, Ruppert AS, Guinn D, Lehman A, Blachly JS, Lozanski A, Heerema NA, Zhao W, Coleman J, Jones D, Abruzzo L, Gordon A, Mantel R, Smith LL, McWhorter S, Davis M, Doong TJ, Ny F, Lucas M, Chase W, Jones JA, Flynn JM, Maddocks K, Rogers K, Jaglowski S, Andritsos LA, Awan FT, Blum KA, Grever MR, Lozanski G, Johnson AJ, Byrd JC. Woyach JA, et al. Among authors: gordon a. J Clin Oncol. 2017 May 1;35(13):1437-1443. doi: 10.1200/JCO.2016.70.2282. Epub 2017 Feb 13. J Clin Oncol. 2017. PMID: 28418267 Free PMC article. Clinical Trial.
Ibrutinib treatment improves T cell number and function in CLL patients.
Long M, Beckwith K, Do P, Mundy BL, Gordon A, Lehman AM, Maddocks KJ, Cheney C, Jones JA, Flynn JM, Andritsos LA, Awan F, Fraietta JA, June CH, Maus MV, Woyach JA, Caligiuri MA, Johnson AJ, Muthusamy N, Byrd JC. Long M, et al. Among authors: gordon a. J Clin Invest. 2017 Aug 1;127(8):3052-3064. doi: 10.1172/JCI89756. Epub 2017 Jul 17. J Clin Invest. 2017. PMID: 28714866 Free PMC article. Clinical Trial.
Prognostic significance of translocations in the presence of mutated IGHV and of cytogenetic complexity at diagnosis of chronic lymphocytic leukemia.
Heerema NA, Muthusamy N, Zhao Q, Ruppert AS, Breidenbach H, Andritsos LA, Grever MR, Maddocks KJ, Woyach J, Awan F, Long M, Gordon A, Coombes C, Byrd JC. Heerema NA, et al. Among authors: gordon a. Haematologica. 2021 Jun 1;106(6):1608-1615. doi: 10.3324/haematol.2018.212571. Haematologica. 2021. PMID: 32414849 Free PMC article.
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
Herman SE, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S, Flynn J, Jones J, Blum KA, Buggy JJ, Hamdy A, Johnson AJ, Byrd JC. Herman SE, et al. Among authors: gordon al. Blood. 2011 Jun 9;117(23):6287-96. doi: 10.1182/blood-2011-01-328484. Epub 2011 Mar 21. Blood. 2011. PMID: 21422473 Free PMC article.
Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib.
Miller CR, Ruppert AS, Heerema NA, Maddocks KJ, Labanowska J, Breidenbach H, Lozanski G, Zhao W, Gordon AL, Jones JA, Flynn JM, Jaglowski SM, Andritsos LA, Blum KA, T Awan F, Rogers KA, Grever MR, Johnson AJ, Abruzzo LV, Hertlein EK, Blachly JS, Woyach JA, Byrd JC. Miller CR, et al. Among authors: gordon al. Blood Adv. 2017 Aug 21;1(19):1584-1588. doi: 10.1182/bloodadvances.2017007302. eCollection 2017 Aug 22. Blood Adv. 2017. PMID: 29296799 Free PMC article.
Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.
Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ. Herman SE, et al. Among authors: gordon al. Blood. 2010 Sep 23;116(12):2078-88. doi: 10.1182/blood-2010-02-271171. Epub 2010 Jun 3. Blood. 2010. PMID: 20522708 Free PMC article.
4,419 results